A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
about
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FNew Therapeutic Approaches in Polycythemia VeraRuxolitinib in the treatment of polycythemia vera: patient selection and special considerationsMethotrexate Is a JAK/STAT Pathway InhibitorDiagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroManagement of polycythaemia vera: a critical review of current data.Safety evaluation of ruxolitinib for treating myelofibrosis.Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsSelective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.Ruxolitinib versus standard therapy for the treatment of polycythemia vera.Ruxolitinib: A Review in Polycythaemia Vera.Experience with ruxolitinib in the treatment of polycythaemia vera.Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Current and future treatment options for polycythemia vera.The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemiaJAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in miceDiagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtableIntracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular TargetsEfficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.Novel and emerging therapies for the treatment of polycythemia veraStat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiencyMyeloid Cell Origins, Differentiation, and Clinical Implications.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?Quality of life in MPN comes of age as a therapeutic target.Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.Structural genomic alterations in primary mediastinal large B-cell lymphoma.Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.Ruxolitinib for the treatment of patients with polycythemia vera.Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
P2860
Q26750696-EC6E902F-78B6-48CC-85C1-C1CE356E3D1CQ26777398-B5F76601-7CFB-4561-8064-614A0D86FEA0Q26795666-8DE9B091-F2B6-46D6-9E02-F6C10CE9C010Q26795677-7B11EECB-260E-463F-9D7B-EF21F22A5DD4Q28078404-080CC836-D2CC-49FA-9A22-2787AA8E2A04Q28546079-50783080-1D73-4C49-A28B-19BCECD040A9Q30315531-BF4FC337-8829-4D25-9BFF-05C7A15C13A9Q31009757-E04E1E26-00B6-40C3-B11E-545E1F299E29Q33415731-54BF05F3-9423-44C9-A58B-EA3179680AC8Q33417217-095CC088-6AE8-421F-998B-C46880CA0C7CQ33419762-C05FCCED-9FDB-4D5E-B703-BC5F9BEE6EF8Q33420037-AD3E5D5E-62F0-4187-9304-620386FE8181Q33425781-E3090DED-FBDD-4599-9454-48B7CEADE1BCQ33605624-FB061337-AC08-4D4C-8C09-6277DA121EAFQ35188877-E64A0878-CEB6-47C2-B2FB-AE297A334E52Q35572748-D4ED6C82-0441-4341-9621-CE6758E80313Q35856790-9C8D1FE0-D4CD-4280-AEAD-F0851484D40AQ36155080-98633EFD-5FA6-45B3-A549-63443AD35A46Q36232824-0AB4097E-25C1-4487-B487-5B76177C55EEQ36266377-42DC0CFA-86C2-4C66-9711-169FA2B9967DQ36679531-42EE4A63-2AF3-4DEE-A83E-3A0EBF354509Q37035925-03E89291-3B39-4522-AAE7-F45D177F642BQ37069633-7190ECAE-B458-4856-A509-D77BB1E5B152Q37304113-13249E17-1260-4F3E-BDB2-75E473149765Q37429070-3533E29B-2977-4348-8C39-3772E188F915Q37555790-FCF0EFAA-1DF8-45D4-8474-06B703C07F7FQ37561170-DEAE498A-A6D9-46F2-ACEA-020E4D36F2A6Q38207079-743F4C6F-AC87-4AE1-91C3-52BF530167E9Q38210664-E8A6324A-2D57-4526-8F3B-0A360DA808FEQ38239580-1CA0F4F0-680D-416C-BFFE-B57DC224D9F7Q38254893-BCDDEEC2-08DF-4AD5-A87D-D70A737754ACQ38255717-7E0838C1-80D8-4393-84AE-954F45CCB5F6Q38267888-36291FD4-7FF7-4F08-AC35-38E2417A71D3Q38292400-2FF29408-EB12-4B44-A217-ED4FCC6FA1AEQ38341625-EBCA4D95-32BF-4303-AF26-249A10477201Q38420817-0B42A33B-CED9-4C42-BFF2-E422F3AAA931Q38484321-4AE4F4F2-6F9B-4CD6-9E31-64D45F4706F6Q38723484-97A928B7-86AA-4130-B1A3-223F1E52397FQ38740700-004F7866-4931-4D35-B9A0-D09FB025E84FQ38796480-497580A5-1BD4-4757-9750-2D696DF09FEF
P2860
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase 2 study of ruxolitinib ...... or intolerant to hydroxyurea.
@ast
A phase 2 study of ruxolitinib ...... or intolerant to hydroxyurea.
@en
type
label
A phase 2 study of ruxolitinib ...... or intolerant to hydroxyurea.
@ast
A phase 2 study of ruxolitinib ...... or intolerant to hydroxyurea.
@en
prefLabel
A phase 2 study of ruxolitinib ...... or intolerant to hydroxyurea.
@ast
A phase 2 study of ruxolitinib ...... or intolerant to hydroxyurea.
@en
P2093
P2860
P50
P356
P1433
P1476
A phase 2 study of ruxolitinib ...... or intolerant to hydroxyurea.
@en
P2093
Alessandro M Vannucchi
Alessandro Rambaldi
Bijoyesh Mookerjee
Chiara Elena
Elisa Rumi
Elisabetta Gattoni
Giovanni Barosi
Hagop M Kantarjian
Mario Cazzola
Nancy Contel
P2860
P304
P356
10.1002/CNCR.28441
P407
P577
2014-02-01T00:00:00Z